Serina Therapeutics, Inc. 8-K

What Happened Serina Therapeutics, Inc. announced and filed a Certificate of Amendment to its First Amended and Restated Certificate of Incorporation with the Delaware Secretary of State, increasing its authorized common stock from 40,000,000 to 125,000,000 shares. The amendment was approved by stockholders at the company’s Annual Meeting and is effective as of June 17, 2026. The 8‑K was signed by CEO Steve Ledger and filed June 24, 2026.

Key Details

• Authorized common shares increased from 40,000,000 to 125,000,000; par value remains $0.0001 per share.
• Certificate of Amendment filed with the Delaware Secretary of State, effective June 17, 2026.
• Amendment was approved by stockholders at the company’s Annual Meeting.
• The filing also references a First Amendment to the Serina Therapeutics 2024 Equity Incentive Plan (filed as Exhibit 10.1).

Why It Matters Increasing authorized shares gives the company legal capacity to issue more common stock in the future for financing, strategic transactions, or equity compensation, but it does not by itself change the number of shares outstanding. Investors should note this change when monitoring potential dilution, future capital raises, or expansions of equity‑based compensation, and watch for any subsequent filings that actually issue new shares or amend outstanding share counts.